单采
家族性高胆固醇血症
医学
低密度脂蛋白单采
脂蛋白(a)
脂蛋白
重症监护医学
疾病
儿科
内科学
胆固醇
血小板
作者
M. Reijman,D. Meeike Kusters,Jaap W. Groothoff,Klaus Arbeiter,Eldad J. Dann,Lotte M. de Boer,Sarah D. de Ferranti,Antonio Gallo,Susanne Greber‐Platzer,Jacob Hartz,Lisa C. Hudgins,Daiana Ibarretxe,Meral Kayıkçıoğlu,Reinhard Klingel,Genovefa Kolovou,Jun Oh,R. Nils Planken,Claudia Stefanutti,Christina Taylan,Albert Wiegman,Claus Peter Schmitt
标识
DOI:10.1016/j.atherosclerosis.2024.117525
摘要
Abstract
Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is used for decades, lowering serum LDL-C levels by more than 70% directly after the treatment. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment goals and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI